Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings Significant EPS Miss Amid PreClinical Stage Operations KNDI Q2 2024 Earnings Modest Profit Amid Limited Disclosure STXS Q1 2026 Earnings LargerThanExpected Loss as Company Continues Strategic Transition FSLR Q1 2026 Earnings EPS Beat Bolstered by Strong Operating Performance and Demand Tailwinds Clearwater Analytics Q1 2026 Earnings EPS Slightly Misses Estimates Stock Slides